Y Mabs Therapeutics earnings were -$29.7M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest YMAB earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$6.8M, down 3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, YMAB reported annual earnings of -$29.7M, with 38.5% growth. The next YMAB earnings date is May 5, 2025.
Y Mabs Therapeutics Earnings Reports & History FAQ
What were Y Mabs Therapeutics's earnings last quarter?
On YMAB's earnings call on Invalid Date, Y Mabs Therapeutics (NASDAQ: YMAB) reported Q4 2024 earnings per share (EPS) of -$0.15, up 650% year over year. Total YMAB earnings for the quarter were -$6.79 million. In the same quarter last year, Y Mabs Therapeutics's earnings per share (EPS) was -$0.02.
The next YMAB earnings date is Invalid Date. Add YMAB to your watchlist to be reminded of Y Mabs Therapeutics's next earnings date.
Is Y Mabs Therapeutics profitable or losing money?
As of the last Y Mabs Therapeutics earnings report, Y Mabs Therapeutics is currently losing money. Y Mabs Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$29.67 million, a 38.45% increase year over year.
What was YMAB's earnings growth in the past year?
As of Y Mabs Therapeutics's earnings date in Invalid Date, Y Mabs Therapeutics's earnings has grown year over year. YMAB earnings in the past year totalled -$29.67 million.
What are Y Mabs Therapeutics's earnings expectations?
The current EPS estimate for Y Mabs Therapeutics's earnings report in Invalid Date is -$0.14.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.